Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,614.22
(
0.19%
)
US TECH 100
29,781.60
(
0.24%
)
Dow Jones
51,107.22
(
0.06%
)
Brent Oil
94.29
(
-1.76%
)
Bitcoin
67,741.56
(
-5.08%
)
News Focus
News Focus

Replies to post #119839 on Biotech Values

Replies to #119839 on Biotech Values
icon url

DewDiligence

05/11/11 3:41 PM

#119840 RE: DFRAI #119839

Having an SPA for an adaptive design is better than not having an SPA, but it’s not as good as having an SPA for a conventional phase-3 trial because there are many variables that, by definition, cannot be preempted.